Drug Profile
ISR 50
Alternative Names: ISR-050; ISR-50Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Isomerase Therapeutics
- Developer Immune System Regulation
- Class Antineoplastics; Antituberculars
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Tuberculosis
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in Sweden
- 28 Feb 2022 No recent reports of development identified for preclinical development in Tuberculosis in Sweden
- 12 Sep 2018 Immune System Regulation announces intention to submit an IND to the US FDA for Cancer